Dr. Jeanmarie Guenot: President And CEO Of Amphivena Therapeutics, Inc.


Jeanmarie Guenot, Ph.D. is Amphivena Therapeutics, Incorporated’s president and CEO. Guenot has been working in the biotechnology and pharmaceutical industry for more than 20 years. She has worked with new and established private and public companies. Jeanmarie has experience in project and alliance management, pharmaceutical R&D, venture capital, business development and corporate and commercial development. CrunchBase makes the point that Guenot also has significant interest and expertise in rebuilding and building a variety of companies. Her current company, Amphivena Therapeutics, develops innovative bifunctional antibody therapies that are used to treat hematologic malignancies.


Dr. Guenot, who has an MBA from The University of Pennsylvania’s The Wharton School and earned a Ph.D. at the University of California, has held several positions before starting her current company. She founded, developed and ran the start-up ophthalmic company incubator SKS Ocular. The company worked on dry AMD as well as other viable technologies and therapies using sustained-release ocular drug delivery for healing macular degeneration, glaucoma and ocular inflammation.


Jeanmarie Guenot provided vital business advice to Hoffmann-La Roche in Shanghai and Basel. Plus she also handled important mergers and acquisitions, licensing and alliance management while serving as PDL Biopharma’s corporate and business development vice president. She also worked on commercial product portfolios and research and development.


Dr. Guenot also negotiated and led co-commercialization and co-development strategic collaboration for the Biogen Idec-PDL 50:50. This dealt with three Phase 2 autoimmune disease and cancer drug candidates. This was an $800 million transaction which included Biogen Idec/PDL and Hoffmann-La Roche splitting a therapeutic candidate and a $100 million equity investment in PDL. Dr. Guenot gave Ophthotech a license to use the oncology drug with ophthalmic indication. She also has experience in project, portfolio and alliance management in ophthalmic diseases, autoimmune diseases, cardiovascular disease, neurology and oncology.


According to Jeanmarie’s Amphivena bio, Dr. Guenot first became involved in business when she built life science companies and managed venture capital for Atlas Venture. Her scientific career began when she was hired at Hoffmann-La Roche to be a principal scientist working on Preclinical R&D. While there she discovered and developed drugs to treat autoimmune diseases, inflammation, metabolic diseases and oncology.

Read more on Jeanmarie’s official website here: http://jeanmarieguenot.com/